| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3777 |
| Trial ID | NCT06285422 |
| Disease | Non-Hodgkin's Lymphoma | Large B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SC262 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID) |
| Year | 2024 |
| Country | United States |
| Company sponsor | Sana Biotechnology |
| Other ID(s) | SC262-101 |
| Cohort 1 | |||||||||||
|
|||||||||||